Need professional-grade analysis? Visit stockanalysis.com
$11.40B
N/A
743
N/A
Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443) trades on SHG in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY31.13, down 3.59% from the previous close.
Over the past year, 688443 has traded between a low of CNY25.09 and a high of CNY37.02. The stock has gained 1.1% over this period. It is currently 15.9% below its 52-week high.
Chongqing Genrix Biopharmaceutical Co. Ltd. A has a market capitalization of $11.40B.
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.
Side-by-side comparison against top Healthcare peers.